CTnI心肌标志物的临床应用及评估

目的了解心肌肌钙蛋白I(CTnI)测定对不同类型病变冠心病(CHO)的诊断价值。方法采用免疫荧光分析法,检测54例各种类型CAO患者包括急性心肌梗死(AMI,23例)、不稳定性心绞痛(UAP,13例)、稳定性心绞痛(SAP,18例)]的CTnI含量,并进行综合分析。结果各类型CAO的CTnI含量均有不同程度的增高,AMI、UAP和SAP的阳性率分别为95.7%、69.2%和5.6%。除SAP与对照组比较,差异无统计学意义(P0.05)外,AMI和UAP与对照组比较,差异均有统计学意义(P0.05)。结论 CTnI是灵敏、特异的心脏心肌标志物,可用于诊断早期AMI、UAP和急性冠状动脉综合征(ACS)患者的危险分层、预后、预测;CTnI浓度增高与冠心病(CHO)多种危险因素有关,CTnI检测是反映冠状动脉粥样硬化病变心肌损伤、坏死的主要指标,对预测和诊断CHO各类型病变动态变化及心血管事件具有重要的应用价值。

Clinical application and evaluation of cardiac biomarker CTnI

Objective]To study the diagnostic value of cardiac troponin I(CTnI) determination on different types of coronary heart diseases.Methods]By suing the fluorescent immunoassay,CTnI content was detected in 54 patients with different types of coronary heart diseases,including 23 cases of acute myocardial infarction(AMI),13 cases of unstable angina pectoris(UAP) and 18 cases of stable angina pectoris(SAP),and the results were analyzed synthetically.Results]CTnI contents in patients with different types of coronary heart diseases increased at different degrees,and the positive rate of AMI,UAP and SAP group was 95.7% and 69.2% and 5.6%,respectively.There was no significant difference between SAP group and the control group(P>0.05),and the differences between AMI,UAP group and the control group were significant(P<0.05).Conclusion]CTnI is a sensitive and specific cardiac biomarker,and it can be used in the risk classification,outcome and prognosis of patients with early AMI,UAP and acute coronary syndrome(ACS).The increasing CTnI content is related to various risk-factors of coronary heart diseases.CTnI determination can reflect the myocardial injury and necrosis of coronary artery atherosclerosis,which has an important application value in the predictions and diagnosis of dynamic change and cardiovascular events of different types of coronary heart diseases.